ZwitterCo has a new line of sanitary superfiltration (SF) spiral membrane elements featuring its second-generation SF technology.

Dairy giant Bel Group will supply its whey waste to food tech startup Standing Ovation for the production of ...

Protein2o ( the leader in clear protein drink industry, proudly announces its nationwide retail expansion with 1,400 Target stores further solidifying its rising presence in the ready-to-drink (RTD) ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

March, 2025 – Each year, millions of tons of whey, enough to fill thousands of Olympic swimming ... who leads this development and holds a Ph.D. in Biotechnology from Tecnológico de Monterrey and is ...

The downsizing is planned for May 12. — Cargo Therapeutics, 84 layoffs in San Carlos. The biotech company is halting development and is closing its San Carlos site. The downsizing is planned for ...

Alcon's acquisition of Aurion Biotech enhances its cell therapy capabilities for eye diseases, with Aurion operating independently under Alcon's support. Aurion's AURN001, an allogeneic cell therapy ...

CINCINNATI (Cincinnati Business Courier) - A growing biotech and pharmaceuticals manufacturer that announced a large investment in Greater Cincinnati a little over a year ago has unveiled new ...

Earlier this week, Novo Nordisk NVO signed an exclusive license agreement with China-based United Biotechnology for an experimental obesity drug in a deal valued at up to $2 billion. Through this ...

Whey is a by-product of cheese manufacturing and one of the largest sources of food loss and waste in the Australian dairy sector, and the country's food industry more broadly. It's the liquid ...

There remains much uncertainty about these measures, however. As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news.

A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. Character Biosciences has landed a $93 million series B to progress its precision ...